Needham & Company LLC Has Lowered Expectations for Boston Scientific (NYSE:BSX) Stock Price

Boston Scientific (NYSE:BSX) had its price objective dropped by research analysts at Needham & Company LLC from $121.00 to $97.00 in a report released on Thursday, MarketBeat reports. The firm currently has a “buy” rating on the medical equipment provider’s stock. Needham & Company LLC’s target price suggests a potential upside of 27.23% from the stock’s current price.

BSX has been the subject of several other reports. Morgan Stanley boosted their target price on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Citigroup cut their price objective on shares of Boston Scientific from $130.00 to $102.00 and set a “buy” rating for the company in a research report on Thursday. Royal Bank Of Canada raised their target price on Boston Scientific from $125.00 to $130.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Finally, Wells Fargo & Company lifted their target price on Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $109.43.

Boston Scientific Stock Performance

Shares of BSX opened at $76.24 on Thursday. The firm has a market capitalization of $113.02 billion, a P/E ratio of 39.30, a PEG ratio of 1.37 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. Boston Scientific has a one year low of $74.86 and a one year high of $109.50. The business has a fifty day moving average of $93.39 and a 200 day moving average of $98.79.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.96% and a net margin of 14.44%.The business had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same period last year, the firm posted $0.70 earnings per share. The business’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, sell-side analysts anticipate that Boston Scientific will post 2.85 EPS for the current year.

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The SEC filing for this sale provides additional information. 0.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Boston Scientific

Several hedge funds have recently modified their holdings of BSX. Vanguard Group Inc. increased its holdings in Boston Scientific by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after acquiring an additional 1,436,550 shares during the last quarter. State Street Corp increased its holdings in shares of Boston Scientific by 1.1% in the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after purchasing an additional 713,379 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Boston Scientific by 2.0% in the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock worth $3,466,320,000 after buying an additional 622,602 shares in the last quarter. Norges Bank bought a new position in Boston Scientific during the second quarter valued at approximately $2,089,937,000. Finally, Invesco Ltd. grew its holdings in Boston Scientific by 0.7% during the 3rd quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider’s stock valued at $1,656,131,000 after buying an additional 111,826 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 beat but mixed outlook — Boston Scientific reported stronger-than-expected Q4 results (revenue growth and EPS beat), showing continued top-line momentum that supports the longer‑term growth story. Q4 results and presentation
• Positive Sentiment: Some analysts still rate BSX as a buy/overweight with mid‑to‑high price targets — several firms left positive ratings (Morgan Stanley set a $118 PT; others keep “outperform/overweight”), indicating continued analyst confidence in long-term upside despite near-term caution. Morgan Stanley PT note
• Neutral Sentiment: Board change announced — Boston Scientific disclosed a planned long‑serving director departure; governance turnover is notable but not currently flagged as material to near‑term operations. Board director departure
• Neutral Sentiment: Unusually active options and volume — options and share volume spiked during the sell‑off, increasing volatility and making short-term price moves more extreme (can amplify both down and up moves). Options activity
• Negative Sentiment: Cautious 2026 guidance and weak electrophysiology sales drove a sharp sell‑off — management’s conservative revenue/growth guidance and softer performance in a key segment prompted a high‑volume liquidation that erased recent gains. Guidance and segment weakness
• Negative Sentiment: Multiple securities‑fraud investigations announced — several law firms have opened inquiries into Boston Scientific’s disclosures around the quarter/guidance, increasing legal and reputational risk. Howard G. Smith investigation Frank R. Cruz investigation
• Negative Sentiment: Insider selling and new lows — CEO share sales and headlines about insider selling coincided with the stock reaching a 12‑month low, which can undermine investor confidence even when fundamentals are mixed. CEO stock sale note 12-month low report
• Negative Sentiment: Widespread analyst price‑target cuts — multiple firms trimmed their 12‑month targets after Q4/guidance, increasing short‑term downside pressure even where ratings remain constructive. Analyst cuts roundup

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.